Heart failure (HF) is a major cause of morbidity and mortality in the United States. While progress in conventional treatments is making steady and incremental gains, there is a critical need to explore new therapeutic approaches. Over the last five years, there has been a tremendous amount of information about microRNAs (miRs) in cardiac diseases. These small noncoding RNAs regulate protein expression by destabilization and/or translational inhibition of target messenger RNAs (mRNAs). Expression of miRs is abnormally regulated in cardiac hypertrophy and heart failure. In fact, miR expression seems to be more sensitive than mRNA to changes in clinical cardiac function. Single miRs tend to regulate numerous effectors within the same functional pathway, producing a coherent physiological response. Targeting miRs can therefore produce beneficial responses in disease states. Stable miR mimetics (agomiRs) and antagonists (antagomiRs) for specific miRs have been developed to prevent or reverse various diseases including experimental heart failure. Recently, our group found that miR25 is a key microRNA that regulates the cardiac sarcoplasmic reticulum calcium ATPase pump, SERCA2a. We showed antimiR25 treatment enhanced cardiac contractility and function through SERCA2a restoration in murine heart failure models. These early results suggest that inhibition of miR25 expression may be a promising therapeutic approach to enhance cardiac function in HF. Our overall hypothesis is that there are optimized sequences and functional structures of miR25 decoys. These decoys efficiently inhibit miR25 activity and consequently improve SERCA2a expression in cardiac myocytes of HF patients.
Heart failure is a major cause of morbidity and mortality in the United States and there is a critical need for novel therapies. In this proposal, we will investigae the role of noncoding microRNA (miR25) in failing hearts. Modulating miR25 expression may be a promising therapeutic approach to enhance cardiac function in heart failure.
|Mayourian, Joshua; Ceholski, Delaine K; Gorski, Przemek A et al. (2018) Exosomal microRNA-21-5p Mediates Mesenchymal Stem Cell Paracrine Effects on Human Cardiac Tissue Contractility. Circ Res 122:933-944|
|Diez-Cuñado, Marta; Wei, Ke; Bushway, Paul J et al. (2018) miRNAs that Induce Human Cardiomyocyte Proliferation Converge on the Hippo Pathway. Cell Rep 23:2168-2174|
|Ceholski, Delaine K; Turnbull, Irene C; Kong, Chi-Wing et al. (2018) Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol 119:147-154|
|Jeong, Dongtak; Yoo, Jimeen; Lee, Philyoung et al. (2018) miR-25 Tough Decoy Enhances Cardiac Function in Heart Failure. Mol Ther 26:718-729|
|Poller, Wolfgang; Dimmeler, Stefanie; Heymans, Stephane et al. (2018) Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J 39:2704-2716|
|Hammoudi, Nadjib; Watanabe, Shin; Bikou, Olympia et al. (2018) Speckle-Tracking Echocardiographic Strain Analysis Reliably Estimates Degree of Acute LV Unloading During Mechanical LV Support by Impella. J Cardiovasc Transl Res :|
|Mayourian, Joshua; Ceholski, Delaine K; Gonzalez, David M et al. (2018) Physiologic, Pathologic, and Therapeutic Paracrine Modulation of Cardiac Excitation-Contraction Coupling. Circ Res 122:167-183|
|Ceholski, Delaine K; Turnbull, Irene C; Pothula, Venu et al. (2017) CXCR4 and CXCR7 play distinct roles in cardiac lineage specification and pharmacologic ?-adrenergic response. Stem Cell Res 23:77-86|
|Cunningham, Thomas J; Yu, Michael S; McKeithan, Wesley L et al. (2017) Id genes are essential for early heart formation. Genes Dev 31:1325-1338|
|Hajjar, Roger J; Ishikawa, Kiyotake; Kovacic, Jason C et al. (2017) Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai Translational Mission. Circ Res 121:1316-1319|
Showing the most recent 10 out of 32 publications